The Impact of Cannabidiol Treatment on Anxiety Disorders: A Systematic Review of Randomized Controlled Clinical Trials
Generalized Anxiety Disorder (GAD) is a common psychiatric condition characterized by persistent and excessive worry, often accompanied by dysautonomic symptoms that significantly impact patients’ well-being. Cannabidiol (CBD), a non-psychoactive compound derived from cannabis, has shown potential a...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-10-01
|
| Series: | Life |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-1729/14/11/1373 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846153179039793152 |
|---|---|
| author | Carly de Faria Coelho Rodolfo P. Vieira Osvaldo Soares Araújo-Junior Pedro Sardinha Leonardo Lopes-Martins Larissa Gomes dos Santos Lucas Danilo Dias Alberto Souza de Sá Filho Patrícia Sardinha Leonardo Sandro Dutra e Silva Rodrigo Alvaro Brandão Lopes-Martins |
| author_facet | Carly de Faria Coelho Rodolfo P. Vieira Osvaldo Soares Araújo-Junior Pedro Sardinha Leonardo Lopes-Martins Larissa Gomes dos Santos Lucas Danilo Dias Alberto Souza de Sá Filho Patrícia Sardinha Leonardo Sandro Dutra e Silva Rodrigo Alvaro Brandão Lopes-Martins |
| author_sort | Carly de Faria Coelho |
| collection | DOAJ |
| description | Generalized Anxiety Disorder (GAD) is a common psychiatric condition characterized by persistent and excessive worry, often accompanied by dysautonomic symptoms that significantly impact patients’ well-being. Cannabidiol (CBD), a non-psychoactive compound derived from cannabis, has shown potential as an anxiolytic through its partial agonism of the 5HT-1A receptor and its negative allosteric modulation of CB1 receptors, which may help mitigate the anxiogenic effects of tetrahydrocannabinol (THC). This study evaluates the impact of CBD on individuals diagnosed with various anxiety disorders, comparing its effects to placebo and conventional pharmaceutical treatments through a systematic review of randomized controlled trials (RCTs). A systematic search of RCTs published between 2013 and 2023 was conducted across three databases using the terms “cannabidiol” and “anxiety”. Out of the 284 articles identified, 11 met the eligibility criteria. The studies reviewed varied widely in terms of the types of anxiety disorders and CBD dosages examined, leading to results that were often contradictory. Despite these conflicting outcomes, the data suggest that CBD may reduce anxiety with minimal adverse effects when compared to a placebo. However, further RCTs with improved methodologies, encompassing a broad range of doses and continuous CBD administration across specific anxiety disorders, are needed. Unlike previous studies and meta-analyses, this review encompasses a broader spectrum of anxiety disorders and a variety of study designs and dosages, providing a more nuanced understanding of CBD’s potential efficacy across different conditions. |
| format | Article |
| id | doaj-art-d1bdf67434ac4969a1ee85b3c41deb99 |
| institution | Kabale University |
| issn | 2075-1729 |
| language | English |
| publishDate | 2024-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Life |
| spelling | doaj-art-d1bdf67434ac4969a1ee85b3c41deb992024-11-26T18:10:06ZengMDPI AGLife2075-17292024-10-011411137310.3390/life14111373The Impact of Cannabidiol Treatment on Anxiety Disorders: A Systematic Review of Randomized Controlled Clinical TrialsCarly de Faria Coelho0Rodolfo P. Vieira1Osvaldo Soares Araújo-Junior2Pedro Sardinha Leonardo Lopes-Martins3Larissa Gomes dos Santos4Lucas Danilo Dias5Alberto Souza de Sá Filho6Patrícia Sardinha Leonardo7Sandro Dutra e Silva8Rodrigo Alvaro Brandão Lopes-Martins9Laboratory of Biophotonics and Experimental Therapeutics—LABITEX, Universidade Evangélica de Goiás—Unievangélica, Av. Universitária Km 3.5, Anápolis 75083-515, GO, BrazilLaboratory of Exercise Immunology, Universidade Evangélica de Goiás—Unievangélica, Av. Universitária Km 3.5, Anápolis 75083-515, GO, BrazilLaboratory of Applied Neurosciences, Universidade Evangélica de Goiás—Unievangélica, Av. Universitária Km 3.5, Anápolis 75083-515, GO, BrazilLaboratory of Applied Neurosciences, Universidade Evangélica de Goiás—Unievangélica, Av. Universitária Km 3.5, Anápolis 75083-515, GO, BrazilLaboratory of Biophotonics and Experimental Therapeutics—LABITEX, Universidade Evangélica de Goiás—Unievangélica, Av. Universitária Km 3.5, Anápolis 75083-515, GO, BrazilLaboratory of New Materials, Post-Graduate Program in Pharmaceutical Sciences, Pharmacology and Therapeutics, Universidade Evangélica de Goiás—Unievangélica, Av. Universitária Km 3.5, Anápolis 75083-515, GO, BrazilLaboratory of Applied Neurosciences, Universidade Evangélica de Goiás—Unievangélica, Av. Universitária Km 3.5, Anápolis 75083-515, GO, BrazilLaboratory of Health Technologies—LATES, Universidade Evangélica de Goiás—Unievangélica, Av. Universitária Km 3.5, Anápolis 75083-515, GO, BrazilLaboratory of Natural History of Cerrado, Post-Graduate Program in Pharmaceutical Sciences, Pharmacology and Therapeutics, Universidade Evangélica de Goiás—Unievangélica, Av. Universitária Km 3.5, Anápolis 75083-515, GO, BrazilLaboratory of Biophotonics and Experimental Therapeutics—LABITEX, Universidade Evangélica de Goiás—Unievangélica, Av. Universitária Km 3.5, Anápolis 75083-515, GO, BrazilGeneralized Anxiety Disorder (GAD) is a common psychiatric condition characterized by persistent and excessive worry, often accompanied by dysautonomic symptoms that significantly impact patients’ well-being. Cannabidiol (CBD), a non-psychoactive compound derived from cannabis, has shown potential as an anxiolytic through its partial agonism of the 5HT-1A receptor and its negative allosteric modulation of CB1 receptors, which may help mitigate the anxiogenic effects of tetrahydrocannabinol (THC). This study evaluates the impact of CBD on individuals diagnosed with various anxiety disorders, comparing its effects to placebo and conventional pharmaceutical treatments through a systematic review of randomized controlled trials (RCTs). A systematic search of RCTs published between 2013 and 2023 was conducted across three databases using the terms “cannabidiol” and “anxiety”. Out of the 284 articles identified, 11 met the eligibility criteria. The studies reviewed varied widely in terms of the types of anxiety disorders and CBD dosages examined, leading to results that were often contradictory. Despite these conflicting outcomes, the data suggest that CBD may reduce anxiety with minimal adverse effects when compared to a placebo. However, further RCTs with improved methodologies, encompassing a broad range of doses and continuous CBD administration across specific anxiety disorders, are needed. Unlike previous studies and meta-analyses, this review encompasses a broader spectrum of anxiety disorders and a variety of study designs and dosages, providing a more nuanced understanding of CBD’s potential efficacy across different conditions.https://www.mdpi.com/2075-1729/14/11/1373cannabidiolanxietypsychiatryneuropsychological effectsRCT |
| spellingShingle | Carly de Faria Coelho Rodolfo P. Vieira Osvaldo Soares Araújo-Junior Pedro Sardinha Leonardo Lopes-Martins Larissa Gomes dos Santos Lucas Danilo Dias Alberto Souza de Sá Filho Patrícia Sardinha Leonardo Sandro Dutra e Silva Rodrigo Alvaro Brandão Lopes-Martins The Impact of Cannabidiol Treatment on Anxiety Disorders: A Systematic Review of Randomized Controlled Clinical Trials Life cannabidiol anxiety psychiatry neuropsychological effects RCT |
| title | The Impact of Cannabidiol Treatment on Anxiety Disorders: A Systematic Review of Randomized Controlled Clinical Trials |
| title_full | The Impact of Cannabidiol Treatment on Anxiety Disorders: A Systematic Review of Randomized Controlled Clinical Trials |
| title_fullStr | The Impact of Cannabidiol Treatment on Anxiety Disorders: A Systematic Review of Randomized Controlled Clinical Trials |
| title_full_unstemmed | The Impact of Cannabidiol Treatment on Anxiety Disorders: A Systematic Review of Randomized Controlled Clinical Trials |
| title_short | The Impact of Cannabidiol Treatment on Anxiety Disorders: A Systematic Review of Randomized Controlled Clinical Trials |
| title_sort | impact of cannabidiol treatment on anxiety disorders a systematic review of randomized controlled clinical trials |
| topic | cannabidiol anxiety psychiatry neuropsychological effects RCT |
| url | https://www.mdpi.com/2075-1729/14/11/1373 |
| work_keys_str_mv | AT carlydefariacoelho theimpactofcannabidioltreatmentonanxietydisordersasystematicreviewofrandomizedcontrolledclinicaltrials AT rodolfopvieira theimpactofcannabidioltreatmentonanxietydisordersasystematicreviewofrandomizedcontrolledclinicaltrials AT osvaldosoaresaraujojunior theimpactofcannabidioltreatmentonanxietydisordersasystematicreviewofrandomizedcontrolledclinicaltrials AT pedrosardinhaleonardolopesmartins theimpactofcannabidioltreatmentonanxietydisordersasystematicreviewofrandomizedcontrolledclinicaltrials AT larissagomesdossantos theimpactofcannabidioltreatmentonanxietydisordersasystematicreviewofrandomizedcontrolledclinicaltrials AT lucasdanilodias theimpactofcannabidioltreatmentonanxietydisordersasystematicreviewofrandomizedcontrolledclinicaltrials AT albertosouzadesafilho theimpactofcannabidioltreatmentonanxietydisordersasystematicreviewofrandomizedcontrolledclinicaltrials AT patriciasardinhaleonardo theimpactofcannabidioltreatmentonanxietydisordersasystematicreviewofrandomizedcontrolledclinicaltrials AT sandrodutraesilva theimpactofcannabidioltreatmentonanxietydisordersasystematicreviewofrandomizedcontrolledclinicaltrials AT rodrigoalvarobrandaolopesmartins theimpactofcannabidioltreatmentonanxietydisordersasystematicreviewofrandomizedcontrolledclinicaltrials AT carlydefariacoelho impactofcannabidioltreatmentonanxietydisordersasystematicreviewofrandomizedcontrolledclinicaltrials AT rodolfopvieira impactofcannabidioltreatmentonanxietydisordersasystematicreviewofrandomizedcontrolledclinicaltrials AT osvaldosoaresaraujojunior impactofcannabidioltreatmentonanxietydisordersasystematicreviewofrandomizedcontrolledclinicaltrials AT pedrosardinhaleonardolopesmartins impactofcannabidioltreatmentonanxietydisordersasystematicreviewofrandomizedcontrolledclinicaltrials AT larissagomesdossantos impactofcannabidioltreatmentonanxietydisordersasystematicreviewofrandomizedcontrolledclinicaltrials AT lucasdanilodias impactofcannabidioltreatmentonanxietydisordersasystematicreviewofrandomizedcontrolledclinicaltrials AT albertosouzadesafilho impactofcannabidioltreatmentonanxietydisordersasystematicreviewofrandomizedcontrolledclinicaltrials AT patriciasardinhaleonardo impactofcannabidioltreatmentonanxietydisordersasystematicreviewofrandomizedcontrolledclinicaltrials AT sandrodutraesilva impactofcannabidioltreatmentonanxietydisordersasystematicreviewofrandomizedcontrolledclinicaltrials AT rodrigoalvarobrandaolopesmartins impactofcannabidioltreatmentonanxietydisordersasystematicreviewofrandomizedcontrolledclinicaltrials |